Mathew Blurton-Jones presents CRISPR-based interventions for a rare brain disorder in mice by substituting defective brain cells with healthy ones. He details experiments demonstrating the efficacy of corrected cells in mitigating brain pathologies. Blurton-Jones emphasizes the need for cautious translation to human trials, advocating gradual cell replacement to preempt potential adverse effects. Additionally, he delves into the implications of microglia in Alzheimer's disease progression and explores potential interconnections among various neurodegenerative conditions. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 38333]